Medical Imaging Corp. (6637) AI Stock Analysis

Medical Imaging Corp.

(TPEx:6637)

Select Model

Rating:62Neutral

Price Target:TWD 54.00▼(-1.10% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by deteriorating cash generation, margin pressure, and weak technical momentum. Attractive valuation and strong revenue growth provide meaningful support, but they do not fully offset the financial-quality risks.

Positive Factors

Long-Term Revenue ExpansionThe near doubling of revenue across the reported period indicates meaningful business expansion and increasing commercial scale. A larger revenue base can support broader customer reach, operating leverage, and reinvestment, giving the company a stronger platform for sustained growth over the coming quarters.

Negative Factors

Cash Flow BreakdownThe shift from positive operating and free cash flow to substantial negative amounts is a significant deterioration in cash generation. If sustained, it could increase reliance on external funding, constrain investment and dividends, and make the company more vulnerable while working capital or investment needs remain elevated.

Medical Imaging Corp. (6637) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 1.45B
Dividend Yield: 8.26%
Average Volume (3M): 31.44K
Price to Earnings (P/E): 9.9
Beta (1Y): 0.45
Revenue Growth: -24.93%
EPS Growth: -28.65%
Country: TW
Employees: 42
Sector: General
Sector Strength: 55
Industry: Medical - Distribution

Medical Imaging Corp. Business Overview & Revenue Model

Company Description

Medical Imaging Corporation, actively operating in China, specializes in providing leasing and management solutions for medical imaging technology. Its comprehensive product portfolio includes sophisticated diagnostic devices such as ultrasound equip...

Medical Imaging Corp. Financial Statement Overview

Summary

Revenue growth and continued profitability are offset by margin compression, higher debt, and sharply negative operating and free cash flow. The score reflects the average of the 78 income statement, 72 balance sheet, and 35 cash flow scores.

Income Statement

78Positive

Balance Sheet

72Positive

Cash Flow

35Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	915.34M	1.16B	829.03M	682.18M	487.29M	604.12M
Gross Profit	296.25M	342.27M	336.09M	328.32M	239.50M	227.10M
EBITDA	237.10M	278.85M	263.68M	215.71M	194.00M	188.73M
Net Income	147.49M	185.54M	165.02M	121.33M	111.60M	76.78M
Balance Sheet
Total Assets	1.92B	1.92B	1.19B	863.20M	762.79M	773.37M
Cash, Cash Equivalents and Short-Term Investments	536.39M	569.74M	487.29M	216.17M	182.92M	124.77M
Total Debt	504.90M	461.97M	94.30M	147.97M	150.17M	245.72M
Total Liabilities	848.39M	795.31M	294.21M	300.94M	259.17M	340.46M
Stockholders Equity	1.07B	1.12B	894.35M	562.25M	503.62M	432.90M
Cash Flow
Free Cash Flow	-43.63M	-322.05M	172.14M	88.64M	211.02M	81.99M
Operating Cash Flow	114.20M	-294.39M	208.23M	168.79M	240.77M	103.71M
Investing Cash Flow	-213.89M	-65.39M	-199.46M	-40.08M	-65.87M	-33.57M
Financing Cash Flow	81.53M	409.03M	98.47M	-63.53M	-146.59M	-51.70M

Medical Imaging Corp. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6637 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6637	62Neutral	TWD 1.46B	9.93	―	8.26%	-24.93%	-28.65%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4729	43Neutral	TWD 1.32B	37.69	―	―	3.32%	82.70%
TW:3516	39Underperform	TWD 1.38B	47.64	―	0.86%	8.10%	276.21%

* General Sector Average

Performance Comparison

TW:6637 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6637	Medical Imaging Corp.	54.60	-22.26	-28.96%
TW:3516	ADO Optronic Corp.	22.65	2.95	14.96%
TW:4729	Mildex Optical Inc.	17.05	-3.35	-16.42%
TW:4980	Jorjin Technologies Inc.	28.25	2.25	8.65%
TW:6857	Acer Medical Inc.	89.90	-28.60	-24.14%
TW:7803	aetherAI Co., Ltd.	12.50	-20.20	-61.77%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Medical Imaging Corp. AI Stock Analysis